{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:47:06Z","timestamp":1778755626860,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Health Serv."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Advances in multiple myeloma (MM) treatment have shifted the therapeutic landscape. Understanding patients' perspectives can assist physicians in helping patients make informed decisions. This study aimed to understand the patient decision-making process and gain insights into patient perspectives on B-cell maturation antigen (BCMA)-targeted therapies for MM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An 18-question survey was completed by patients with MM enrolled in HealthTree\u00ae Cure Hub, an online portal helping patients with plasma cell dyscrasias navigate their disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From October 28, 2022, to January 12, 2023, 325 patients with MM participated in the survey. The mean age (standard deviation) of the respondents was 66 (8) years; 54% were female and 90% were White. Among 218 patients with complete clinical records in the database, the median (min, max) lines of therapy (LOT) was 2 (1,16). Among 61 (28%) patients who had received \u22654 LOTs, 55 (90%) were triple-class exposed. Of the 290 patients who responded to the question about openness to new therapies, 76 (26%) were open to trying a new therapy immediately and 125 (43%) wanted more information on safety and efficacy. Most respondents reported likely or very likely to try a BCMA CAR T-cell therapy (60%) or a bispecific antibody (74%) and some needed more information to decide (16% for CAR T-cell therapy and 13% for bispecific antibody). The most requested information included efficacy, side effects (SEs), eligibility, and administration process for both CAR T-cell and bispecific therapies. When 2 therapies with the same efficacy and duration of response were offered, 69% of respondents would prefer the therapy with a lower risk of severe SEs but requires continuous dosing with no treatment-free interval, and 31% preferred a therapy given once followed by a treatment-free interval but with a potentially higher risk of severe SEs. To receive an effective therapy, the top acceptable trade-offs included frequent monitoring of SEs and initiating a new therapy in a hospital setting, and the least acceptable compromise was caregiver burden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study found a high level of openness in patients with MM to try BCMA-targeted therapies. Information on efficacy, safety, availability, and eligibility may assist patients on decision-making.<\/jats:p><\/jats:sec>","DOI":"10.3389\/frhs.2024.1354760","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T14:34:25Z","timestamp":1713969265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group"],"prefix":"10.3389","volume":"4","author":[{"given":"Jay R.","family":"Hydren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dee","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan W.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingcao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Arturo","family":"Hurtado Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Ahlstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"B1","year":""},{"key":"B2","year":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1182\/blood-2022-167617","article-title":"Burden of hospitalization before and after a disease progression following triple-class exposure in patients with relapsed and refractory multiple myeloma","volume":"140","author":"Harper","year":"2022","journal-title":"Blood"},{"key":"B4","first-page":"Doc10","article-title":"Evaluating patients\u2019 preferences for multiple myeloma therapy, a discrete-choice-experiment","volume":"5","author":"Muhlbacher","year":"2008","journal-title":"Psychosoc Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4081\/oncol.2018.374","article-title":"Treat patient, not just the disease: holistic needs assessment for haematological cancer patients","volume":"12","author":"Islam","year":"2018","journal-title":"Oncol Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.14514","article-title":"Guidelines for screening and management of late and long-term consequences of myeloma and its treatment","volume":"176","author":"Snowden","year":"2017","journal-title":"Br J Haematol"},{"key":"B8","year":""},{"key":"B9","year":""},{"key":"B10","year":""},{"key":"B11","year":""},{"key":"B12","year":""},{"key":"B13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B16","year":""},{"key":"B17","doi-asserted-by":"publisher","first-page":"e2100141","DOI":"10.1200\/CCI.21.00141","article-title":"Healthtree cure hub: a patient-derived, patient-driven clinical cancer information platform used to overcome hurdles and accelerate research in multiple myeloma","volume":"6","author":"Sweeney","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2200053","DOI":"10.1200\/cci.22.00053","article-title":"Erratum","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12885-022-10458-x","article-title":"Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study","volume":"23","author":"Dombeck","year":"2023","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40271-021-00501-7","article-title":"Patient perceptions regarding multiple myeloma and its treatment: qualitative evidence from interviews with patients in the United Kingdom, France, and Germany","volume":"14","author":"He","year":"2021","journal-title":"Patient"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1027353","DOI":"10.3389\/fonc.2022.1027353","article-title":"What matters most to patients with multiple myeloma? A pan-European patient preference study","volume":"12","author":"Janssens","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12885-019-5467-x","article-title":"Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study","volume":"19","author":"Parsons","year":"2019","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"686165","DOI":"10.3389\/fmed.2021.686165","article-title":"Patient preferences for multiple myeloma treatments: a multinational qualitative study","volume":"8","author":"Janssens","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1603","DOI":"10.1002\/cnr2.1603","article-title":"The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies","volume":"5","author":"Crawford","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1007\/s00520-022-06979-7","article-title":"Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed\/refractory multiple myeloma","volume":"30","author":"Nathwani","year":"2022","journal-title":"Support Care Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2217\/fon-2023-0020","article-title":"Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA","volume":"19","author":"Ribbands","year":"2023","journal-title":"Future Oncol"}],"container-title":["Frontiers in Health Services"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2024.1354760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T14:34:29Z","timestamp":1713969269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2024.1354760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":27,"alternative-id":["10.3389\/frhs.2024.1354760"],"URL":"https:\/\/doi.org\/10.3389\/frhs.2024.1354760","relation":{},"ISSN":["2813-0146"],"issn-type":[{"value":"2813-0146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"article-number":"1354760"}}